* AtriCure Inc ATRC.OQ ATRC.O is expected to show a rise
in
quarterly revenue when it reports results on February 15 for
the period ending December 31 2023
* The Mason Ohio-based company is expected to report a
17.8% increase in revenue to $103.681 million from $88.03
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.The company's guidance on January 8
2024, for the period ended December 31, was for revenue of
$106.500 million.
* LSEG's mean analyst estimate for AtriCure Inc is for a
loss
of 23 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AtriCure
Inc is
$54.50, above its last closing price of $33.52.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.31 -0.31 -0.20 Beat 35.8
Jun. 30 2023 -0.29 -0.30 -0.11 Beat 62.8
Mar. 31 2023 -0.34 -0.34 -0.23 Beat 32.1
Dec. 31 2022 -0.17 -0.18 -0.09 Beat 48.8
Sep. -0.25 -0.25 -0.27 Missed -6.8
30 2022
Jun. 30 2022 -0.29 -0.29 -0.32 Missed -9.3
Mar. 31 2022 -0.31 -0.32 -0.33 Missed -3.2
Dec. 31 2021 -0.29 -0.29 -0.30 Missed -3.4
This summary was machine generated February 13 at 22:33 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)